1057652-79-5 Usage
General Description
"Methyl 2-methoxy-4-methyl-5-nitrobenzoate" is a chemical compound with the molecular formula C10H11NO5. It is a yellow solid substance that is used in the manufacture of various pharmaceuticals and agrochemicals. methyl 2-methoxy-4-methyl-5-nitrobenzoate is known for its nitro-group, which can potentially contribute to its reactivity and biological activity. It is important to handle this chemical with care as it may pose health hazards if not properly managed. Further research and testing may be needed to fully understand its potential uses and risks in different applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1057652-79-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,7,6,5 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1057652-79:
(9*1)+(8*0)+(7*5)+(6*7)+(5*6)+(4*5)+(3*2)+(2*7)+(1*9)=165
165 % 10 = 5
So 1057652-79-5 is a valid CAS Registry Number.
1057652-79-5Relevant articles and documents
ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-1" PATHWAY AND METHODS OF USE THEREOF
-
Paragraph 0238, (2020/03/02)
The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.
ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF
-
Paragraph 0566, (2020/03/01)
The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.
Synthesis and Neuroleptic Activity of N--2-methoxy-5-sulfonamidobenzamides
Ogata, Masaru,Matsumoto, Hiroshi,Kida, Shiro,Shiomi, Teruo,Eigyo, Masami,Hirose, Katsumi
, p. 1137 - 1141 (2007/10/02)
A series of some novel N-benzamides involving replacement of the sulfamoyl group in sulpiride with a sulfonamido group was synthesized and tested for dopamine receptor blockade.In comparison with sulpiride, several compounds were considerably more potent than sulpiride as dopamine receptor blockers.The structure-activity relationships are discussed.
